Anti-human Immunodeficiency Virus Type 1 Activity and in Vitro Toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a Novel Heterocyclic Nucleoside Analog

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1991 Jul 1

PMID 1929298

Citations 51

Authors

H Soudeyns

X I Yao

Q Gao

B Belleau

J L Kraus

N Nguyen-Ba

B Spira

M A Wainberg

Affiliations

Soon will be listed here.

Abstract

We describe a novel nucleoside analog, 2'-deoxy-3'-thiacytidine (BCH-189), in which the 3' carbon of the ribose ring of 2'-deoxycytidine has been replaced by a sulfur atom. In MT-4 T cells, this compound had significant time- and dose-dependent antiviral activity against five different strains of human immunodeficiency virus type 1 (HIV-1) (mean 50% inhibitory dose, 0.73 microM); known 3'-azido-3'-deoxythymidine (AZT)-resistant HIV-1 variants did not exhibit cross-resistance to it. BCH-189 also suppressed HIV-1 replication in the U937 monocytoid cell line as well as in primary cultures of human peripheral blood mononuclear cells; in these latter systems, suppression was fuller and longer lasting than that induced by AZT. Moreover, BCH-189 was less toxic than AZT in cell culture. BCH-189 may be a promising drug for the treatment of HIV-1-associated disease.

Citing Articles

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.

Mimtsoudis I, Tsachouridou O, Akinosoglou K, Metallidis S Viruses. 2024; 16(9).

PMID: 39339868 PMC: 11437411. DOI: 10.3390/v16091392.

Steady-state pharmacokinetics of lamivudine in end-stage kidney failure persons with detectable and undetectable HIV-1 RNA in peritoneal dialysis effluent.

Mooko T, Bisiwe F, Mondleki E, Morobadi M, Chikobvu P, Nyaga M Eur J Med Res. 2024; 29(1):374.

PMID: 39026368 PMC: 11256402. DOI: 10.1186/s40001-024-01972-8.

Antiviral Chemotherapy in Avian Medicine-A Review.

Szotowska I, Ledwon A Viruses. 2024; 16(4).

PMID: 38675934 PMC: 11054683. DOI: 10.3390/v16040593.

The Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations.

Omoteso O, Milne M, Aucamp M Int J Anal Chem. 2022; 2022:3510277.

PMID: 35154325 PMC: 8837449. DOI: 10.1155/2022/3510277.

Advances in Therapeutic -Nucleosides and -Nucleic Acids with Unusual Handedness.

Dantsu Y, Zhang Y, Zhang W Genes (Basel). 2022; 13(1).

PMID: 35052385 PMC: 8774879. DOI: 10.3390/genes13010046.

References

Sundstrom C, Nilsson K . Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976; 17(5):565-77. DOI: 10.1002/ijc.2910170504. View

Boulerice F, Bour S, Geleziunas R, Lvovich A, Wainberg M . High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol. 1990; 64(4):1745-55. PMC: 249312. DOI: 10.1128/JVI.64.4.1745-1755.1990. View

Mitsuya H, Weinhold K, Furman P, St Clair M, Lehrman S, Gallo R . 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985; 82(20):7096-100. PMC: 391317. DOI: 10.1073/pnas.82.20.7096. View

Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D . Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986; 1(8481):575-80. DOI: 10.1016/s0140-6736(86)92808-4. View

Mitsuya H, Broder S . Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986; 83(6):1911-5. PMC: 323194. DOI: 10.1073/pnas.83.6.1911. View

Stewart S, Fujimoto J, Levy R . Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. J Immunol. 1986; 136(10):3773-8. View

Gartner S, Markovits P, Markovitz D, Kaplan M, Gallo R, Popovic M . The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986; 233(4760):215-9. DOI: 10.1126/science.3014648. View

Maddon P, Dalgleish A, McDougal J, Clapham P, Weiss R, Axel R . The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986; 47(3):333-48. DOI: 10.1016/0092-8674(86)90590-8. View

Furman P, Fyfe J, St Clair M, Weinhold K, Rideout J, Freeman G . Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986; 83(21):8333-7. PMC: 386922. DOI: 10.1073/pnas.83.21.8333. View

10.

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

11.

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View

12.

Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S . 3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem. 1987; 30(8):1270-8. DOI: 10.1021/jm00391a003. View

13.

Hamamoto Y, Nakashima H, Matsui T, Matsuda A, Ueda T, Yamamoto N . Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother. 1987; 31(6):907-10. PMC: 284209. DOI: 10.1128/AAC.31.6.907. View

14.

Lee M, Sano K, MORALES F, IMAGAWA D . Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus. J Clin Microbiol. 1987; 25(9):1717-21. PMC: 269314. DOI: 10.1128/jcm.25.9.1717-1721.1987. View

15.

Yarchoan R, Perno C, Thomas R, Klecker R, Allain J, Wills R . Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988; 1(8577):76-81. DOI: 10.1016/s0140-6736(88)90283-8. View

16.

Fauci A . The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988; 239(4840):617-22. DOI: 10.1126/science.3277274. View

17.

Larder B, Darby G, Richman D . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989; 243(4899):1731-4. DOI: 10.1126/science.2467383. View

18.

Tersmette M, Gruters R, de Wolf F, de Goede R, Lange J, Schellekens P . Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989; 63(5):2118-25. PMC: 250628. DOI: 10.1128/JVI.63.5.2118-2125.1989. View

19.

Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao X, Fanning M . Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989; 3(7):411-5. DOI: 10.1097/00002030-198907000-00001. View

20.

Larder B, Kemp S . Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989; 246(4934):1155-8. DOI: 10.1126/science.2479983. View